New Big Data Approach Predicts Drug Toxicity in Humans
September 21, 2016
Researchers can now predict the odds of experimental drugs succeeding in clinical trials, thanks to a new data-driven approach developed by Weill Cornell Medicine scientists. The method detects toxic side effects that may disqualify drugs from human use, giving drug developers an early warning before initiating clinical trials, according to a new study published Sept. 15 inCell Chemical Biology.
Virtual Vision
September 10, 2016
In the 1966 film Fantastic Voyage, physicians were shrunk down to microscopic size to travel inside the human body and save a dying patient. Now, researchers at Weill Cornell Medicine are using virtual reality goggles to bring that fantasy to life—with the aim of improving cancer care.
Why we need precision medicine—now
September 1, 2016
The launch of President Obama’s Precision Medicine Initiative is putting a cutting-edge approach to research and patient care on the map. Academic medical centers have been pioneering the development of precision medicine for more than a decade—and now it’s time for the biopharmaceutical industry to get deeper in the game.
From ‘tache to test: Movember Foundation funds research into non-invasive blood test for metastatic prostate cancer
August 2, 2016
In order to benefit from the latest advances in precision medicine, Himisha Beltran, M.D., has to subject her prostate cancer patients to invasive biopsies that can be painful, expensive, difficult to perform, and not always feasible.
But she is hoping to harness new genomic sequencing technologies to track tumor activity from a simple blood draw, and a $1 million grant from the Prostate Cancer Foundation may help make the dream a clinical reality.
EXaCT-1 Precision Medicine Cancer Test Validated for Clinical Usage
July 19, 2016
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research. The scientists say their findings, published July 20 in NPJ Genomic Medicine, validate the test, called Weill Cornell Medicine EXaCT-1, and demonstrate its feasibility in a clinical setting.
EIPM creates big data solution
July 12, 2016
One of the biggest challenges in precision medicine is what to do with the mountain of data generated from the sequencing of each tumor – how to parse out the relevant information and make it accessible and useful to the physicians making treatment decisions. Ultimately, such data should be available for a function called Clinical Decision Support. This function as defined by the Federal Office of the National Coordinator for Health Information Technology is “knowledge and person-speci
EIPM to participate in White House-Led Precision Medicine Initiative
July 8, 2016
Moving with what has been cited as unprecedented speed, the National Institutes of Health (NIH) has chosen a collaboration of four New York institutions — Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Hospital and NYC Health + Hospitals/Harlem — to launch a landmark longitudinal research study as a part of President Barack Obama’s Precision Medicine Initiative (PMI).
The PMI Cohort Program aims to collect health, lifestyle and genetic information from 1 million or more people in the United States in efforts to improve disease treatment and prevention.
Defining Our Cancer Moonshot
July 2, 2016
In what evolved into a cancer moonshot think tank, a special event was held at Weill Cornell Medicine on June 29, one of 270 held in tandem across the United States convened by Vice President Joe Biden, with a national summit at Howard University in Washington, DC.
Sequencing Reveals Molecular Underpinnings of Aggressive Prostate Cancer Subtype
February 9, 2016
A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, Weill Cornell Medicine and University of Trento investigators discovered in a new study. The scientists say their findings may lead to more effective ways to diagnose and treat neuroendocrine prostate cancer.
New 3D goggles help doctors search for mutations in cancerous tumors
January 27, 2016
Researchers in New York are now using virtual reality to delve deep inside the human body in hopes of unlocking a cure for cancer.
Researchers at Weill Cornell Medicine developed the genome sequencing software application.
Doctors wear a virtual reality headset to visualize protein structures in 3D space, searching for mutations in tumors.